Jefferies 2017 Global Healthcare Conference June 6-9

The Jefferies 2017 Global Healthcare Conference will be taking place June 6-9 in New York City. Following the success of last year’s event, with over 350 participating companies and 2,500 attendees, the conference will again feature an extensive range of public & private healthcare companies across the Biopharmaceuticals, Life Sciences, Healthcare Services, Healthcare IT and Medical Technology…

Anavex President & CEO Christopher U. Missling, PhD, to present preclinical data on ANAVEX 2-73™ at the Epilepsy Foundation’s Antiepileptic Drug Trials XIV Conference on May 19.

Anavex President & CEO Christopher U. Missling, PhD, will be presenting preclinical data on ANAVEX 2-73™ at the Epilepsy Foundation’s Antiepileptic Drug Trials XIV Conference on May 19, 2017. May 17-19, 2017 | Turnberry Isle Miami Hotel  | Aventura, Florida Antiepileptic Drug Trials XIV Conference | May 2017 Friday, May 19, 2017 3:10pm ET ANAVEX 2-73, A…

Anavex President & CEO Christopher U. Missling, PhD, to participate in a roundtable discussion at the World Orphan Drug Congress USA, on April 21.

Anavex President & CEO Christopher U. Missling, PhD, to participate in a roundtable discussion at the World  Orphan Drug Congress USA, Friday, at 12:20 PM on April 21. Wardmar Park Marriott Washington, DC Roundtable 4: Partnerships- successful collaboration between a rare disease foundation and a pharmaceutical company to advance preclinical and clinical research in Rett…

Anavex Life Sciences to Present at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases AD/PD™ 2017

NEW YORK, March 29, 2017 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, announced today data presentations related to Anavex’s Alzheimer’s disease pipeline…

Anavex Life Sciences to Present at Oppenheimer 27th Annual Healthcare Conference

NEW YORK — March 15, 2017 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that Christopher U. Missling, PhD, President…